[go: up one dir, main page]

BRPI0917661B8 - produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina - Google Patents

produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina

Info

Publication number
BRPI0917661B8
BRPI0917661B8 BRPI0917661A BRPI0917661A BRPI0917661B8 BR PI0917661 B8 BRPI0917661 B8 BR PI0917661B8 BR PI0917661 A BRPI0917661 A BR PI0917661A BR PI0917661 A BRPI0917661 A BR PI0917661A BR PI0917661 B8 BRPI0917661 B8 BR PI0917661B8
Authority
BR
Brazil
Prior art keywords
compound
macitentan
product
endowed
combination
Prior art date
Application number
BRPI0917661A
Other languages
English (en)
Inventor
Clozel Martine
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917661(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0917661A2 publication Critical patent/BRPI0917661A2/pt
Publication of BRPI0917661B1 publication Critical patent/BRPI0917661B1/pt
Publication of BRPI0917661B8 publication Critical patent/BRPI0917661B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan. a invenção refere-se a um produto que contém o composto da fórmula (i) abaixo ou um sal farmaceuticamente aceitável deste composto, em combinação com pelo menos um composto que é dotado de propriedades agonistas do receptor de prostaciclina (ip), ou um sal farmaceuticamente aceitável do mesmo.
BRPI0917661A 2008-08-13 2009-08-12 produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina BRPI0917661B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
PCT/IB2009/053553 WO2010018549A2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (3)

Publication Number Publication Date
BRPI0917661A2 BRPI0917661A2 (pt) 2015-12-01
BRPI0917661B1 BRPI0917661B1 (pt) 2019-12-17
BRPI0917661B8 true BRPI0917661B8 (pt) 2021-05-25

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917661A BRPI0917661B8 (pt) 2008-08-13 2009-08-12 produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina

Country Status (30)

Country Link
US (3) US8809334B2 (pt)
EP (2) EP3300729B1 (pt)
JP (3) JP5764061B2 (pt)
KR (1) KR101678699B1 (pt)
CN (1) CN102099026B (pt)
AR (1) AR073031A1 (pt)
AU (1) AU2009280843B2 (pt)
BR (1) BRPI0917661B8 (pt)
CA (1) CA2731370C (pt)
CY (2) CY1119826T1 (pt)
DK (2) DK2315587T3 (pt)
ES (2) ES2763176T3 (pt)
HK (1) HK1253355B (pt)
HR (2) HRP20171917T1 (pt)
HU (2) HUE036071T2 (pt)
IL (1) IL211143A0 (pt)
LT (2) LT3300729T (pt)
MA (1) MA32614B1 (pt)
MX (1) MX350011B (pt)
MY (1) MY178894A (pt)
NO (1) NO2315587T3 (pt)
NZ (1) NZ591601A (pt)
PL (2) PL3300729T3 (pt)
PT (2) PT3300729T (pt)
RU (1) RU2519161C2 (pt)
SI (2) SI3300729T1 (pt)
SM (2) SMT201700592T1 (pt)
TW (1) TWI446911B (pt)
WO (1) WO2010018549A2 (pt)
ZA (1) ZA201101900B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615898B8 (pt) 2005-09-12 2021-05-25 Actelion Pharmaceuticals Ltd composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
CN104761509A (zh) 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
PT3300729T (pt) 2008-08-13 2020-01-20 Actelion Pharmaceuticals Ltd Composições terapêuticas contendo macitentan
WO2014110491A1 (en) 2013-01-11 2014-07-17 Theratrophix Llc Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
CA3109851C (en) * 2018-09-14 2024-02-20 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
WO2020128017A1 (en) 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
PH12022551294A1 (en) 2019-11-29 2023-11-20 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
EP4456897A1 (en) 2021-12-31 2024-11-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1097239A (en) 1976-05-11 1981-03-10 Salvador Moncada Enzymatic preparation of prostacyclin and its salts
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) * 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
ES2260318T3 (es) * 2000-12-18 2006-11-01 Actelion Pharmaceuticals Ltd. Nuevas sulfamidas y su utilizacion como antagonistas del receptor de endotelina.
MXPA03005393A (es) * 2000-12-19 2003-09-25 Merck Patent Gmbh Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (pt) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
ATE423103T1 (de) * 2002-12-02 2009-03-15 Actelion Pharmaceuticals Ltd Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
BRPI0615898B8 (pt) * 2005-09-12 2021-05-25 Actelion Pharmaceuticals Ltd composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
SI2254570T1 (sl) 2008-02-20 2014-03-31 Actelion Pharmaceuticals Ltd. Kombinacija, obsegajoča paklitaksel, za zdravljenje raka na jajčnikih
PT3300729T (pt) 2008-08-13 2020-01-20 Actelion Pharmaceuticals Ltd Composições terapêuticas contendo macitentan

Also Published As

Publication number Publication date
JP5956026B2 (ja) 2016-07-20
BRPI0917661A2 (pt) 2015-12-01
PL3300729T3 (pl) 2020-04-30
IL211143A0 (en) 2011-04-28
DK3300729T3 (da) 2020-01-20
JP2011530581A (ja) 2011-12-22
EP2315587A2 (en) 2011-05-04
PT3300729T (pt) 2020-01-20
MY178894A (en) 2020-10-21
CN102099026B (zh) 2012-08-29
AU2009280843B2 (en) 2015-03-05
HK1253355B (en) 2020-06-19
HUE036071T2 (hu) 2018-06-28
ZA201101900B (en) 2012-08-29
TWI446911B (zh) 2014-08-01
WO2010018549A2 (en) 2010-02-18
US9173881B2 (en) 2015-11-03
US8809334B2 (en) 2014-08-19
PT2315587T (pt) 2018-01-31
MX2011001625A (es) 2011-03-29
CY1122641T1 (el) 2021-03-12
RU2011109084A (ru) 2012-09-20
ES2652590T3 (es) 2018-02-05
SMT201700592T1 (it) 2018-03-08
HK1253355A1 (en) 2019-06-14
JP2015180683A (ja) 2015-10-15
US20110136818A1 (en) 2011-06-09
SMT201900740T1 (it) 2020-01-14
CA2731370C (en) 2017-03-14
KR20110045006A (ko) 2011-05-03
LT2315587T (lt) 2018-01-10
HUE047767T2 (hu) 2020-05-28
CN102099026A (zh) 2011-06-15
JP5764061B2 (ja) 2015-08-12
NO2315587T3 (pt) 2018-03-24
MA32614B1 (fr) 2011-09-01
JP2015187148A (ja) 2015-10-29
CA2731370A1 (en) 2010-02-18
DK2315587T3 (en) 2018-01-02
US20160022678A1 (en) 2016-01-28
EP3300729A1 (en) 2018-04-04
HRP20171917T1 (hr) 2018-02-09
LT3300729T (lt) 2020-01-10
US9597331B2 (en) 2017-03-21
BRPI0917661B1 (pt) 2019-12-17
PL2315587T3 (pl) 2018-03-30
NZ591601A (en) 2012-12-21
MX350011B (es) 2017-08-22
EP2315587B1 (en) 2017-10-25
JP5956025B2 (ja) 2016-07-20
HRP20192204T1 (hr) 2020-03-06
SI3300729T1 (sl) 2020-02-28
EP3300729B1 (en) 2019-10-09
AR073031A1 (es) 2010-10-06
ES2763176T3 (es) 2020-05-27
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
SI2315587T1 (en) 2018-04-30
US20140329824A1 (en) 2014-11-06
AU2009280843A1 (en) 2010-02-18
WO2010018549A3 (en) 2010-07-29
TW201010985A (en) 2010-03-16
CY1119826T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
BRPI0917661B8 (pt) produto, composição farmacêutica e uso da combinação de macitentan com um composto que é dotado de propriedades agonistas do receptor de prostaciclina
CY1120089T1 (el) Παραγωγα ουριας ή φαρμακολογικως αποδεκτα αλατα εξ' αυτων χρησιμα ως αγωνιστες του παρομοιου με υποδοχεα πεπτιδιου φορμυλιου 1(fprl-1)
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
MX2009006304A (es) Nuevos compuestos de oxadiazol.
BRPI0708965B8 (pt) composição farmacêutica de metilnaltrexona
ECSP088623A (es) Derivados de azepinoindol como agentes farmacéuticos
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
MX358617B (es) Formulaciones de inhibidores de dpp iv.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CL2007003604A1 (es) Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer.
BRPI0615898B8 (pt) composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
BRPI0916235B8 (pt) composto, composição farmacêutica, e, uso do composto ou da composição
MX2009000884A (es) Derivados de piridizinona.
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
BRPI0813218A2 (pt) Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
BR112013030939A2 (pt) derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo
GT200700064A (es) Agonistas de ep2
UY31736A (es) Derivados sustituidos de pirazol y su uso
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2787 DE 04-06-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.